{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:34:37Z","timestamp":1790620477614,"version":"4.1.0"},"reference-count":32,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100014422","name":"Eli Lilly Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014422","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>\n              Migraine is a highly prevalent neurological disorder and a leading cause of disability worldwide. Although triptans and non-steroidal anti-inflammatory drugs are widely used, a substantial proportion of patients show inadequate responses. Lasmiditan, a selective 5-HT1\n              <jats:sub>F<\/jats:sub>\n              receptor agonist introduced in Japan in January 2022, represents a novel acute treatment option that lacks vasoconstrictive activity and can be prescribed even in patients with cardiovascular risk. However, little is known about the trend of its long-term real-world use.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To characterize 2-year lasmiditan prescription patterns using time-series clustering.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>A retrospective observational study using nationwide health insurance claims data in Japan.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Data were extracted from the REZULT database for patients aged \u2a7e15\u2009years diagnosed with migraine (ICD-10 code G43) between January 2022 and December 2024. Prescription claims were analyzed in 90-day intervals for up to 24\u2009months after the initial lasmiditan prescription. Time-series clustering was applied to identify subgroups with distinct trajectories of lasmiditan use.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Lasmiditan was prescribed to 21,199 of 167,461 (12.7%) migraine patients (mean age 33.8\u2009\u00b1\u200910.3\u2009years; 76.6% female). In the first 3\u2009months, 86.2% received 50\u2009mg, 12.8% received 100\u2009mg, and 1.0% received both doses. About half were also prescribed analgesics, 66.7% triptans, and 33.9% prophylactic drugs. Lasmiditan prescriptions were gradually tapered over 2\u2009years, with the most common long-term pattern being combination therapy with analgesics and triptans. Clustering identified three groups: Cluster 1 (massively continuous use), Cluster 2 (gradual tapering), and Cluster 3 (early discontinuation).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>This nationwide claims-based study provides the first real-world evidence of long-term lasmiditan prescribing patterns. The identification of three distinct trajectories highlights the heterogeneity of clinical practice. It underscores the need for further research on lasmiditan\u2019s optimal use, particularly regarding combination therapy and potential medication overuse.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1177\/17562864251381900","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:12:37Z","timestamp":1760011957000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Time-series clustering analysis for treatment pattern of lasmiditan for 2\u2009years from the initial prescription"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0192-5430","authenticated-orcid":false,"given":"Masahito","family":"Katsuki","sequence":"first","affiliation":[{"name":"Insight Science Foundation Ireland Research Centre for Data Analytics, School of Human and Health Performance, Dublin City University, Dublin, Ireland"},{"name":"Physical Education and Health Center, Nagaoka University of Technology, 1603-1, Kamitomiokamachi, Nagaoka, Niigata 940-2137, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Yamada","sequence":"additional","affiliation":[{"name":"Japan System Techniques Co., Ltd. (JAST), Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taisuke","family":"Ichihara","sequence":"additional","affiliation":[{"name":"Japan System Techniques Co., Ltd. (JAST), Minato-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiko","family":"Matsumori","sequence":"additional","affiliation":[{"name":"Sendai Headache and Neurology Clinic, Sendai, Miyagi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-2982.1997.1701015.x"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01889-x"},{"key":"e_1_3_4_4_2","first-page":"344","article-title":"Nervous system disorders collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"23","author":"GBD","year":"2021","unstructured":"GBD, 2021. Nervous system disorders collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol 2024; 23: 344\u2013381.","journal-title":"Lancet Neurol"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1012-1"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231151419"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-023-00842-x"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz134"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000006641"},{"key":"e_1_3_4_10_2","first-page":"755","article-title":"Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients","volume":"61","author":"Sakai F","year":"2021","unstructured":"Sakai F, Takeshima T, Homma G, et al. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients. J Headache Pain 2021; 61: 755\u2013765.","journal-title":"J Headache Pain"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241305381"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024241258695"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01745-y"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02304-0"},{"key":"e_1_3_4_15_2","first-page":"1601","article-title":"Evaluation of 2-hour post-dose efficacy of lasmiditan for the acute treatment of difficult-to-treat migraine attacks","volume":"60","author":"Tepper SJ","year":"2020","unstructured":"Tepper SJ, Vasudeva R, Krege JH, et al. Evaluation of 2-hour post-dose efficacy of lasmiditan for the acute treatment of difficult-to-treat migraine attacks. J Headache Pain 2020; 60: 1601\u20131615.","journal-title":"J Headache Pain"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-025-00709-7"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.3390\/neurolint16030048"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S304373"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00415-0"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231226177"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3390\/life14010096"},{"key":"e_1_3_4_22_2","article-title":"Treatment patterns, characteristics, and probable acute medication overprescription among patients with migraine in Japan: a retrospective cross-sectional and longitudinal analysis of health insurance claims data","volume":"16","author":"Katsuki M","year":"2024","unstructured":"Katsuki M, Matsumori Y, Ichihara T, et al. Treatment patterns, characteristics, and probable acute medication overprescription among patients with migraine in Japan: a retrospective cross-sectional and longitudinal analysis of health insurance claims data. Cureus 2024; 16: e75928.","journal-title":"Cureus"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417738202"},{"key":"e_1_3_4_24_2","volume-title":"[Clinical Practice Guideline for Headache Disorders 2021] (Japanese)","author":"Headache Clinical Practice Guideline Development Committee","year":"2021","unstructured":"Headache Clinical Practice Guideline Development Committee. [Clinical Practice Guideline for Headache Disorders 2021] (Japanese). Tokyo: Igaku-Shoin, 2021."},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/head.14482"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102421989232"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-021-01343-2"},{"key":"e_1_3_4_28_2","article-title":"The efficacy of Japanese herbal kampo medicine as an acute and prophylactic medication to treat chronic daily headache and medication overuse headache: single arm retrospective study","volume":"14","author":"Katsuki M","year":"2022","unstructured":"Katsuki M, Kashiwagi K, Kawamura S, et al. The efficacy of Japanese herbal kampo medicine as an acute and prophylactic medication to treat chronic daily headache and medication overuse headache: single arm retrospective study. Cureus 2022; 14: e25419.","journal-title":"Cureus"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.20.2599"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-024-01722-5"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2021.1971179"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1177\/0333102420920006"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa211"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251381900","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864251381900","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864251381900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:20:09Z","timestamp":1760426409000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864251381900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":32,"alternative-id":["10.1177\/17562864251381900"],"URL":"https:\/\/doi.org\/10.1177\/17562864251381900","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"article-number":"17562864251381900"}}